Skip to main content

Arsenic trioxide liposomes: Encapsulation efficiency and in vitro stability

Kallinteri, Paraskevi, Fatouros, Dimitrios, Klepetsanis, Pavlos, Antimisiaris, Sophia G. (2004) Arsenic trioxide liposomes: Encapsulation efficiency and in vitro stability. Journal of Liposome Research, 14 (1-2). pp. 27-38. ISSN 0898-2104. (doi:10.1081/LPR-120039661) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:18615)

Plain Text
Language: English

Restricted to Repository staff only
[thumbnail of Voula_publications.txt]
Official URL:


The use of arsenic-containing compounds in cancer therapy is currently being reconsidered, after the recent approval of arsenic trioxide (Trisenox(R)) for the treatment of relapsed promyelocytic leukemia (PML). In an attempt to prepare a carrier system to minimize the toxicity of this drug, the aim of this study is to prepare and characterize liposomes encapsulating arsenic trioxide (ATO). For this, we prepared different types of liposomes entrapping ATO: large multilamellar (MLV), sonicated (SUV) and dried reconstituted vesicles (DRV). The techniques used were: thin film hydration, sonication and the DRV method, respectively. Two lipid compositions were studied for each liposome type, EggPC/Chol (1: 1) and DSPC/Chol (1: 1). After liposome preparation, drug encapsulation was evaluated, by measuring arsenic in liposomes. For this, energy-dispersive X-ray fluorescence spectroscopy or atomic absorption was used. In addition, the retention of the drug in the liposomes was evaluated after incubating the liposomes in buffer at 37degreesC. The experimental results reveal that encapsulation of ATO in liposomes ranges between 0.003 and 0.506 mol/ mol of lipid, and is highest in the DRV vesicles and lowest in the small unilamellar vesicles, as anticipated. Considering the in vitro stability of ATO-encapsulating liposomes: 1) For the PC/Chol liposomes (DRV and MLV), after 24 hours of incubation, more than 70% (or 90% in some cases) of the initially encapsulated amount of ATO was released. 2) The liposomes composed of DSPC/Chol could retain substantially higher amounts of ATO, especially the DRV liposomes (54% retained after 24 h). 3) In the case of PC/Chol, temperature of incubation has no effect on the ATO release after 24 hours, but affects the rate of ATO release in the MLV liposomes, while for the DSPC/Chol liposomes there is a slight increase (statistically insignificant) of ATO release at higher temperature.

Item Type: Article
DOI/Identification number: 10.1081/LPR-120039661
Additional information: 855OX Times Cited:9 Cited References Count:22
Uncontrolled keywords: arsenic trioxide liposome stability arsenic membrane permeation acute promyelocytic leukemia normal-cells apoptosis arsonoliposomes prednisolone inhibition viability culture cancer lines
Subjects: Q Science
R Medicine > RC Internal medicine > RC254 Neoplasms. Tumors. Oncology
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Paraskevi Kallinteri
Date Deposited: 29 May 2009 14:28 UTC
Last Modified: 16 Nov 2021 09:56 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

Kallinteri, Paraskevi.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.